Package Leaflet: Information for the User
Furosemide Pharma Combix 40 mg Tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Package Leaflet
Furosemide Pharma Combix 40 mg tablets is a diuretic belonging to the group of sulfonamides. It acts by increasing urine elimination (diuretic) and reducing blood pressure (antihypertensive).
Always under the prescription of your doctor, this medicine is indicated for the treatment of:
Read carefully the instructions provided in section 3. “How to take Furosemide Pharma Combix”.
Do not take Furosemide Pharma Combix
If you are pregnant, see the section “Pregnancy, breastfeeding, and fertility”.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Furosemide Pharma Combix.
Be especially careful with this medicine:
During your treatment with this medicine, periodic control of your blood levels of sodium, potassium, and creatinine will generally be required, especially if you suffer from severe fluid loss, due to vomiting, diarrhea, or intense sweating. Dehydration or hypovolemia, as well as any significant electrolyte and acid-base balance alterations, must be corrected. Treatment interruption may be required.
Elderly patients with dementia who are taking risperidone must be especially careful with the concomitant use of risperidone and furosemide. Risperidone is a medicine used to treat certain mental illnesses, such as dementia (a disease characterized by several symptoms: memory loss, speech problems, thinking problems).
Use in athletes
This medicine contains furosemide, which can produce a positive result in doping tests.
Use of Furosemide Pharma Combix with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Inform your doctor if you are being treated with medicines for:
The effect of treatment may be affected if furosemide is used at the same time as other medicines.
Some substances may have their toxicity increased in the ear or kidneys if administered together with this medicine. Therefore, if they are administered concomitantly, it is because there are medical reasons that require it.
Among these substances are:
The concomitant use of furosemide with other medicines may weaken the effect of these medicines, such as:
In other cases, concomitant use may increase the effects of these medicines, such as:
Some medicines for inflammation and pain (non-steroidal anti-inflammatory drugs, including acetylsalicylic acid) and medicines for epilepsy (phenytoin) may reduce the effect of furosemide.
Furosemide may increase the toxicity of salicylates.
This medicine and sucralfate should not be administered concomitantly, with an interval of less than 2 hours, as the effect of furosemide may be reduced.
Medicines such as probenecid and methotrexate or other medicines that have significant renal elimination may reduce the effect of furosemide. In high-dose treatment, they may increase serum levels and increase the risk of adverse effects due to furosemide or concomitant administration.
The following substances may increase the risk of reducing potassium levels in the blood (hypokalemia) if administered with furosemide:
Some electrolyte alterations (for example, a decrease in blood potassium levels (hypokalemia) or magnesium (hypomagnesemia)) may increase the toxicity of some medicines (for example, digitalis medicines and medicines that induce the QT interval prolongation syndrome).
Patients undergoing treatment with furosemide who receive high doses of certain cephalosporins (antibiotics) may suffer from a decrease in kidney function.
The concomitant administration of furosemide and cyclosporin A may increase the risk of secondary gouty arthritis due to an increase in blood urea levels and kidney urea elimination problems.
Those patients at high risk of suffering from nephropathy (kidney disease) due to contrast media who receive furosemide are more likely to suffer from kidney function deterioration.
The administration of furosemide together with risperidone in elderly patients with dementia could increase mortality.
High doses of furosemide administered with levothyroxine may lead to an initial transient increase in free thyroid hormones, followed by a general decrease in total thyroid hormone levels.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
If you are pregnant, you will only use furosemide if there are medical reasons that require it.
During breastfeeding, do not administer furosemide. In the case that its administration is essential, your doctor may require you to interrupt breastfeeding, as furosemide passes into breast milk.
Driving and using machines
This medicine may cause dizziness or drowsiness. This can happen more often at the start of treatment, when your doctor increases the dose, or if you consume alcohol. Do not drive or use tools or machines if you feel dizzy or drowsy.
Some side effects (e.g., a pronounced undesirable decrease in blood pressure) may impair the ability to concentrate and react, and therefore constitute a risk in situations where these skills are especially important (e.g., operating vehicles or machinery).
Furosemide Pharma Combix 40 mg tablets contain lactose
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Furosemide Pharma Combix 40 mg tablets contain sodium
This medicine contains less than 23 mg of sodium (1 mmol) per tablet, which is essentially “sodium-free”.
Follow exactly the administration instructions of this medicine indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Remember to take your medicine.
Take Furosemide Pharma Combix on an empty stomach, swallowing it whole and with sufficient liquid.
If you think the action of this medicine is too strong or too weak, tell your doctor or pharmacist.
Your doctor will prescribe the lowest sufficient dose to produce the desired effect.
In adultsit is recommended to start treatment with half, one, or two tablets (20 to 80 mg of furosemide) daily. The maintenance dose is half to one tablet per day, and the maximum dose will be indicated by your doctor and will depend on your response to treatment.
Use in children
In infants and children, it is recommended to administer 2 mg/kg of body weight daily, up to a maximum of 40 mg per day.
Your doctor will indicate the duration of your treatment with this medicine. Do not stop treatment before.
If you take more Furosemide Pharma Combix than you should
In case of overdose or accidental ingestion, consult your doctor or go to the emergency department of the nearest hospital, accompanied by this leaflet, or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount ingested.
An accidental overdose could lead to a severe decrease in blood pressure (which may evolve into shock), kidney problems (acute renal failure), coagulation problems (thrombosis), delirium, flaccid paralysis of soft muscles, apathy, and confusion.
No specific antidote is known.
In case of overdose, treatment will be based on symptoms.
If you forget to take Furosemide Pharma Combix
Do not take a double dose to make up for forgotten doses.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects have been grouped by frequency:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Very rare(may affect up to 1 in 10,000 people)
Frequency not known(cannot be estimated from the available data)
As with other diuretics, after prolonged administration of this medicine, there may be an increase in sodium, chloride, water, potassium, calcium, and magnesium elimination. These alterations are manifested with intense thirst, headache, confusion, muscle cramps, painful contraction of the muscles, especially in the limbs (tetany), muscle weakness, alterations in heart rhythm, and gastrointestinal symptoms.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects that are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not store above 25°C. Store in the original packaging to protect from light.
Do not use this medicine after the expiry date stated on the packaging after CAD. The expiry date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medicines at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition of Furosemida Pharma Combix
Appearance of the Product and Package Contents
White or almost white, round, flat tablets with beveled edges, scored with "40" on one face and notched on the other.
The tablet can be divided into equal doses.
Green, transparent PVC-Aluminum blisters in packages containing 10 or 30 tablets.
Marketing Authorization Holder
Laboratorios Combix, S.L.U.
C/Badajoz 2, Edificio 2
28223 Pozuelo de Alarcón (Madrid)
Spain
Manufacturer
Zydus France
ZAC Les Hautes Patures
Parc d'activités des Peupliers
25 Rue des Peupliers
92000 Nanterre
France
or
Centre Spécialités Pharmaceutiques
ZAC des Suzots
35 rue de la Chapelle
63450 Saint Amant Tallende
France
or
Netpharmalab Consulting Services
Crta. De Fuencarral, 22
28108 Alcobendas (Madrid)
Spain
or
Pharmex Advanced Laboratories, S.L.
Ctra. A-431 Km. 19
14720 Almodóvar del Río (Córdoba)
Spain
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/